Yes, Lacosamide Can Be Given Intravenously
Lacosamide, sold as Vimpat, is approved for intravenous (IV) administration as an alternative to oral dosing, particularly when patients cannot swallow tablets or need rapid seizure control.[1] The IV formulation delivers the same 50 mg/mL concentration as oral options, allowing equivalent dosing without adjusting amounts.[1]
How Is IV Lacosamide Administered?
Administer IV lacosamide over 10-15 minutes to avoid infusion-related side effects like dizziness or nausea. Use a compatible diluent like saline or dextrose, and it can be given via peripheral or central lines. Daily doses match oral regimens—typically 200-400 mg split twice daily for adults with partial-onset seizures.[1][2] Switch to oral when possible without a washout period due to matching bioavailability.[1]
When Do Doctors Choose IV Over Oral?
Clinicians use IV lacosamide in hospital settings for acute epilepsy exacerbations, post-surgery, or during oral intake restrictions (e.g., intubation or nausea). It's common in ICU epilepsy management or status epilepticus protocols as adjunctive therapy with drugs like levetiracetam.[2][3] Studies show similar efficacy and tolerability to oral forms, with faster onset possible via IV.[3]
What Side Effects Occur with IV Dosing?
IV administration carries risks like injection-site reactions, cardiac conduction changes (e.g., PR interval prolongation), or hypersensitivity. Monitor ECG in patients with heart conditions. Common issues mirror oral use: dizziness (30%), headache (15%), and somnolence (10%). Overdose risks increase with rapid infusion.[1][2]
How Does IV Lacosamide Compare to IV Levetiracetam or Fosphenytoin?
| Drug | Typical IV Dose | Infusion Time | Key Advantages | Common Drawbacks |
|------|-----------------|---------------|----------------|------------------|
| Lacosamide | 200-400 mg/day | 10-15 min | Novel mechanism (slow sodium channel inactivation); less sedation | Cardiac monitoring needed; higher cost |
| Levetiracetam | 1000-3000 mg/day | 15 min | Broad-spectrum; renal clearance | Behavioral side effects |
| Fosphenytoin | 15-20 mg PE/kg load | 5-10 min/kg | First-line for status epilepticus | Hypotension; infusion rate limits |
Lacosamide offers a unique sodium channel target, making it suitable when others fail, but it lacks phenytoin's rapid loading speed.[3]
Availability, Pricing, and Patents
Vimpat IV is widely available generically in the US since 2023. A vial costs $20-50 uninsured. No active patents block generics; exclusivity ended in 2022.4
Sources
[1]: Vimpat Prescribing Information (UCB)
[2]: Epilepsy Foundation Guidelines
[3]: NEJM Review on IV Antiepileptics